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Letters to the Editorwell-documented excess long-term
mortality associated with uncorrected
severe aortic stenosis. In contrast,
recently published follow-up data
from the PARTNER trial3 showed
that among 1-year survivors, mortality
during year 2 of follow-up was signif-
icantly lower among TAVR patients
than among SM patients (18% vs
35%; hazard ratio, 0.58; P¼ .02). Do-
ble and colleagues’ approach1 is
therefore very likely to have underes-
timated the survival benefit that
TAVR provides for inoperable
patients.
Finally, in their model for high-risk
surgical candidates, Doble and col-
leagues1 assumed that the increased
risk of stroke with TAVR relative to
SAVR observed in the first year of
follow-up in the PARTNER trial
would continue at a constant rate
through the 20-year time horizon of
the model. Detailed analyses of neuro-
logic events in the PARTNER trial,4 as
well as recently published longer-term
follow-up data,5 suggest that after the
first 30 days of follow-up, stroke rates
for TAVR and SAVR were similar.
We believe that Doble and col-
leagues’ cost-effectiveness model1
should be updated in light of these im-
portant new data. If this were to be
done, the articles conclusions could
be significantly altered.
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COMPARING COLLOIDS IN
CARDIAC SURGERY?
To the Editor:
The publication by Navickis and
colleagues1 highlights a subject with
conflicting results in the literature,
the effect of hydroxyethyl starch
(HES) on bleeding after cardiac sur-
gery. Their study included 18 trials
with 970 patients reported between
1982 and 2008. The primary end point
was postoperative blood loss during
the first 24 postoperative hours, and
secondary end points were reoperation
for bleeding and blood product trans-
fusion within the same period. Na-
vickis and colleagues1 concluded that
HES 450/0.7 and 200/0.5 increased
postoperative blood loss, reoperation
rates and blood product transfusion
relative to albumin, with the statement
that despite the lack of sufficient direct
data for HES 130/0.4, its effects could
be assumed equivalent to those of HES
200/0.5 on the basis of head-to-head
comparisons.
In this valuable meta-analysis, we
think that there is yet another topic
to be discussed. The deleterious ef-
fects of HES solutions on bleeding
have been emphasized, but the possi-
ble positive effects of albumin onof Thoracic and Cardiovascular Surgecoagulation were not discussed. The
older meta-analysis by the same
group published in 2001 discussed
this topic in detail.2 In that article,
they stated that albumin, with its anti-
oxidant and free-radical scavenging
activity, may serve to avert bleeding
after cardiopulmonary bypass
(CPB).2 They also declared that albu-
min was shown to block erythrocyte
crenation caused by CPB and to pre-
serve functional and morphologic in-
tegrity of platelets, which are heavily
affected during CPB. They specu-
lated that the difference in bleeding
tendency could be attributable to the
deleterious effect of HES solutions
alone or in combination with protec-
tive effects of albumin. Lange and as-
sociates3 in their recent and very
detailed review on use of colloids in
cardiac surgery, defined the anticoag-
ulant action of albumin while sum-
marizing the characteristics of
colloids.3 Many controversial results
are being published regarding effects
of colloids on coagulation, so the ef-
fects of albumin on coagulation could
be detailed in this valuable meta-
analysis.
We believe that the discussion on
HES products and their effects on co-
agulation will continue. In particular,
since the retraction of the publications
of Boldt, who made substantial contri-
butions to the colloid-colloid and
colloid-crystalloid debates in favor
of HES, the subject has shifted to
a more complicated pattern, leading
readers to a more skeptical approach.
Physicians can benefit greatly from
meta-analyses such as that of Navickis
and colleagues.1 We as readers thank
the authors for sharing their knowl-
edge and the experience of their
detailed research.
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http://dx.doi.org/10.1016/
j.jtcvs.2012.08.075Reply to the Editor:
Our thanks to Durukan and col-
leagues for their positive comments
about our meta-analysis on bleeding
after cardiopulmonary bypass (CPB).1
Weagree that it is important to consider
the role of albumin in preserving
coagulation system function among
patients undergoingCPB. In particular,
CPB places these patients at risk for
acquired transient platelet dysfunction
attended by diffuse nonsurgical post-
operative bleeding.
A protective effect against hemor-
rhage is suggested by observations in
cardiac surgical patients with albumin
deficiency. In a prospective study of
5168 consecutive patients undergoing
coronary artery bypass grafting, preop-
erative hypoalbuminemia (serumalbu-
min<25 g $ L1) was an independent
risk factor of reexploration for bleed-
ing, with an odds ratio (OR) of 1.4
(95% confidence interval [CI],
1.0-2.1; P ¼ .04) after adjustment for
17 other variables.2 Preoperative hypo-
albuminemia was also an independent
risk factor for mortality in that study
(OR, 2.0; 95% CI, 1.3-3.0; P ¼ .002).
In a meta-analysis of 21 controlled
clinical trials with 1346 total patients,
extracorporeal circuit priming with al-
bumin maintained on-bypass platelet310 The Journal of Thoracic and Ccounts at a significantly higher level
than that seen with crystalloid alone.3
Furthermore, albumin priming was
significantly associated with postop-
erative reductions in thrombocytope-
nia, blood loss, and reoperations for
bleeding relative to crystalloid-alone
priming in a retrospective study of
377 patients undergoingCPB. In a ran-
domized trial, addition of albumin to
a priming solution containing artificial
colloid (dextran 70) also resulted in
significantly higher platelet counts as
long as 48 h after CPB, with signifi-
cantly less blood loss from the medi-
astinal drains.
Albumin is capable of modulating
platelet activity through biologically
specific mechanisms. Platelet aggreg-
ability can be modulated both by com-
plexes of fatty acids bound to albumin
and by nitric oxide–albumin adduct.
Albumin also binds with high affinity
to platelet-activating factor, thereby
reducing its activity, and this binding
occurs exclusively in domain II of
the albumin molecule extending
from polypeptide chain amino acid
position 240 to 386.
As Lange and coauthors4 acknowl-
edge, it is accepted that albumin
does not interfere with coagulation,
other than possibly by hemodilution.
Those authors nevertheless cite two
pieces of contrary evidence, neither
concerned with cardiac surgery. First,
after in vitro dilution of blood samples
from patients scheduled for elective
general surgery, albumin impaired
thromboelastographically assessed
coagulation to a greater extent than
normal saline solution or hydrox-
yethyl starch 450/0.7. However, in 3
randomized trials of colloid use
in vivo among patients undergoing
CPB, 1 involving pump priming and
the other 2 involving postoperative
volume expansion, albumin signifi-
cantly improved clotting as measured
by thromboelastography compared
with hydroxyethyl starch 120/0.7,
130/0.4, 200/0.5, or 450/0.7.1
Second, in a subgroup analysis of
data from the SAFE (Saline versusardiovascular Surgery c January 2013Albumin Fluid Evaluation) study, ac-
tivated partial thromboplastin time
on day 2 increased by 7% in patients
receiving albumin while decreasing
2% in recipients of normal saline so-
lution.5 The SAFE study investigators
conceded that this difference was
‘‘small and thus of questionable clini-
cal importance.’’5 Furthermore, the
difference can be readily explained
by greater hemodilution in the albu-
min group. Thus the ratio of saline so-
lution to albumin infused during the
first 2 days of the SAFE study was
only 1.4, whereas in a randomized
trial of patients undergoing CPB, the
ratio needed for equivalent plasma
volume expansion was 5.8.
From a physiologic perspective, it
appears highly unlikely that albumin,
the most abundant protein in plasma,
would specifically interfere with co-
agulation. The components of the co-
agulation system have evolved to
function under constant exposure to
serum albumin concentrations of ap-
proximately 35 to 50 g $ L1 during
normal conditions.
Albumin remains the criterion stan-
dard for fluid management in cardiac
surgery. A chief advantage, either for
extracorporeal circuit priming or peri-
operative volume expansion, is main-
tenance of a competent coagulation
system.
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